FDA Approves Krystexxa (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to Krystexxa with methotrexate compared to Krystexxa alone Trial data showed a greater than 30 percentage-point increase in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news